Background: All evidence regarding benefits and harms of rivaroxaban for stroke prevention
has not been appraised yet. Study Question: What are the comparative effectiveness and …

Background The use of warfarin reduces the rate of ischemic stroke in patients with atrial
fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor …

An effective anticoagulation therapy is required for patients with atrial fibrillation because it
presents a significant risk of stroke. The current study evaluates the relative safety as well as …

The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage
regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A …

Atrial fibrillation (AF) poses a substantial risk of stroke, necessitating effective
anticoagulation therapy. This systematic review and meta-analysis (SRMA) evaluates the …

Aims The aim of this study was to determine the net clinical benefit (NCB) of rivaroxaban
compared with warfarin in patients with atrial fibrillation. Methods This was a retrospective …

Introduction: Registries and non-interventional studies offer relevant and complementary
information to clinical trials, since they have a high external validity. Areas covered: The …

Real-world data are a well-recognized component within the drug lifecycle, and such data
are generated from a range of sources and study designs, including claims databases …

Atrial fibrillation (AF) is an increasingly common cause of stroke and systemic embolism.
While warfarin has been the mainstay of stroke prevention in patients with AF, newer novel …

Objective: To ascertain the clinical profile, management and rates of thromboembolic and
bleeding complications in a contemporary cohort of patients with nonvalvular atrial …